Immune Thrombocytopenia Market to Reach USD 3.33 Billion by 2026; The Launch of New Products And Pipeline Of Therapeutic Molecules To Aid Growth

The global immune thrombocytopenia market size is projected to reach USD 3.33 Billion by 2026, driven by advancements in intravenous treatment options. According to a report published by Fortune Business Insights, titled “Immune Thrombocytopenia Market Size, Share & Industry Analysis, By Type (Acute Immune Thrombocytopenia, and Chronic Immune thrombocytopenia), By Treatment (Thrombopoietin Receptor Agonist, Immunoglobulins, Corticosteroids, and Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Others) and Regional Forecast, 2019-2026,” the market was valued at USD 2.99 Billion in 2018. The growing prevalence of the disease will enable growth of the market at a steady CAGR, projected to be around 0.54% from 2019-2026.

Immune thrombocytopenia (ITP) is a serious blood disorder that is characterized by abnormally low level of platelet count in the human body. The disease, also called by the name idiopathic thrombocytopenic purpura, is a rare disorder that normally occurs due to injuries, infections, or other wounds. The severity of the disease has led to a huge emphasis on immune thrombocytopenia treatment options, with a collective aim off detection and prevention of the disease at an early stage.  The disease affects few people every year and the drugs used for treatment have been categorized as orphan drugs, due to fewer cases of this disorder. As ITP can only be diagnosed during a regular blood check-up, there is a growing awareness regarding the need for availing blood check-up’s at frequent intervals. Although there are fewer cases of ITP currently, there has been a gradual rise in the incidence of the disease in recent years, which turn will offer a platform for market growth.

Acute Immune Thrombocytopenia to Emerge as the Leading Segment

Based on disease type, the report classifies the immune thrombocytopenia market into acute ITP and chronic ITP. Among these types, the chronic ITP is projected to hold a dominant market share in the coming years, owing to the high prevalence of the disease than the acute type. Chronic ITP is likely to witness a gradual decrease in terms of revenue generation, given the fact that the costs of treatment associated with the disease is high. Moreover, the launch of low-cost bio-similars for the treatment of this disease will help reduce the diagnosis of this disease, which in turn will contribute to a decline in this segment. As a result, the acute immune thrombocytopenia segment will exhibit a higher growth rate in the coming years.

To get a detailed report summary and research scope of this market, click here:

https://www.fortunebusinessinsights.com/industry-reports/immune-thrombocytopenia-itp-market-101682

Thrombopoietin Receptor Agonists Segment Will Hold a Dominant Market Share

On the basis of treatment, the market has been segmented into thrombopoietin receptor agonists, immunoglobulins, and corticosteroids. The report breaks down the ongoing immune thrombocytopenia market trends and highlights a few areas of the market that will be emphasized upon, more than others. Among the several treatment options currently available, the immunoglobulins type is likely to register faster adoption rate than others.

The increasing adoption of the treatment can be attributed to low cost of the treatment, coupled with high efficiency. Moreover, advancements in intravenous immunoglobulins will contribute to the growth of this segment. Although immunoglobulin adoption is gathering pace, the current market is dominated by the thrombopoietin receptor dominates the market, accounting for over 50% share of the global market.

Besides disease type and treatment options, the market has also been classified into distribution channels into hospital pharmacy and retail pharmacy. Additionally, the report classifies the market based on regional demographics into North America, Latin America, Europe, the Middle East and Africa, and Asia Pacific. Driven by improving healthcare reimbursement policies and growing awareness regarding blood disorders, the ITP market in North America will emerge dominant in the coming years. A few of the major companies that are projected to draw wider customer attention over others include:

• Amgen Inc.


• Novartis AG


• Rigel Pharmaceuticals, Inc.


• Dova Pharmaceuticals


• Grifols S.A


• CSL Limited


• Octapharma AG


• Intas Pharmaceuticals Ltd.


• Saol Therapeutics

The global immune thrombocytopenia market is segmented based on: